Kuros Biosciences AG
CSBTF
Rank in Stocks
#8768
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to... Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
Share Price
$25.00
Last synced: 2026-11-06
Market Cap
$976.73M
Change (1 day)
0.00%
Change (1 year)
-31.03%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Kuros Biosciences AG (CSBTF)
Category
Healthcare
Operating Margin for Kuros Biosciences AG (CSBTF)
Operating Margin as of November 2026 TTM: 6.01%
According to Kuros Biosciences AG's latest financial reports, its current operating margin (TTM) is 6.01%. At the end of 2025 the company had an operating margin of 6.04%.
Operating Margin history for Kuros Biosciences AG from 2004 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 6.01% | -0.50% |
| 2025 | 6.04% | -191.38% |
| 2024 | -6.61% | -83.18% |
| 2023 | -39.30% | -47.43% |
| 2022 | -74.76% | 17.81% |
| 2021 | -63.46% | -78.05% |
| 2020 | -289.16% | -35.00% |
| 2019 | -444.83% | -76.83% |
| 2018 | -1,919.86% | -36.88% |
| 2017 | -3,041.76% | 51.19% |
| 2016 | -2,011.88% | -19,651.80% |
| 2015 | 10.29% | -100.54% |
| 2014 | -1,893.70% | -18.61% |
| 2013 | -2,326.60% | 89.64% |
| 2012 | -1,226.82% | -2.24% |
| 2011 | -1,254.87% | 7,157.78% |
| 2010 | -17.29% | -94.22% |
| 2009 | -299.07% | 146.98% |
| 2008 | -121.09% | 423.52% |
| 2007 | -23.13% | -99.52% |
| 2006 | -4,846.82% | 620.48% |
| 2005 | -672.72% | 14.42% |
| 2004 | -587.94% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -93.58% |
US
|
|
| -149.01% | -124.79% |
US
|
|
| 25.57% | -95.75% |
AU
|
|
| 31.23% | -94.80% |
BE
|
|
| 29.35% | -95.12% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Kuros Biosciences AG's operating margin
What is Kuros Biosciences AG's operating margin?
Kuros Biosciences AG's operating margin is 6.01%, as of Nov 2026.
What was Kuros Biosciences AG's operating margin in 2025?
In 2025, Kuros Biosciences AG's operating margin was 6.04%, compared with -6.61% in 2024.
How has Kuros Biosciences AG's operating margin changed since 2020?
From 2020 to 2025, Kuros Biosciences AG's operating margin was highest in 2025 (6.04%) and lowest in 2020 (-289.16%).
How does Kuros Biosciences AG's operating margin compare with similar companies?
Kuros Biosciences AG's operating margin (6.01%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.